Latest Breaking News On - Jeroen rovers - Page 2 : comparemela.com

Mendus Phase 1 vididencel clinical trial results in AML and

Press Release Stockholm, Sweden, November 3, 2023 Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in.

United statesNoord hollandErik mantingCancer center amsterdamAmerican society of hematologyErasmus university medical centerHigh risk myelodysplastic syndromeAcute myeloid leukemia patients receivingPrincipal investigatorJeroen roversChief medical officerNasdaq stockholmAmerican societyOrphan drug designationFast track designationNorthx biologics

Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data

Press Release Stockholm, Sweden, November 2, 2023 Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data Three abstracts.

San diego convention centerUnited statesSan diegoErik mantingSefland haukeland university hospitalBergen universityAmerican society of hematologyAmerican societyAnnual meetingCalifornia decemberJeroen roversHumoral immune responses is associatedDurable remissionsMaintenance treatmentEarly phaseInvestigational therapies

Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program.

United statesCorey davisJorn kaspersHans nijmanAlex karlsson parraHaoxiao zuoMario brkuljErik mantingGerty schreibeltSatwinder kaur singhAmerican society of hematologyLifesci advisorsRadboud institute for molecular life sciencesDepartment of tumor immunologyValency communicationsRadboud university medical centre

Mendus receives U S FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration .

United statesCorey davisMario brkuljErik mantingAmerican society of hematologyValency communicationsDrug administrationLifesci advisorsEuropean medicines agencyFast track designationAcute myeloid leukemiaOrphan drug designationAdvanced therapy medicinal productJeroen roversChief medical officerAmerican society

Mendus AB: Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023

Mendus AB: Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMario brkuljErik mantingCorey davisClinical research excluding trialsAmerican association for cancer researchLifesci advisorsValency communicationsAmerican associationCancer researchAnnual meetingJeroen roversChief medical officerHigh grade serous ovarian cancerImmunomodulatory agentsNasdaq stockholm